Gain Therapeutics’ (GANX) “Buy” Rating Reiterated at HC Wainwright

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $8.00 target price on the stock. HC Wainwright’s price target would indicate a potential upside of 479.71% from the company’s previous close.

Other analysts have also recently issued research reports about the stock. Chardan Capital reiterated a “buy” rating and issued a $6.00 price target on shares of Gain Therapeutics in a research note on Wednesday, March 27th. Oppenheimer reiterated an “outperform” rating and issued a $9.00 target price on shares of Gain Therapeutics in a research report on Tuesday, April 23rd.

Gain Therapeutics Stock Performance

NASDAQ GANX opened at $1.38 on Thursday. The business has a 50-day moving average price of $1.95 and a 200-day moving average price of $3.19. The firm has a market cap of $24.91 million, a price-to-earnings ratio of -0.92 and a beta of 0.35. Gain Therapeutics has a twelve month low of $1.11 and a twelve month high of $5.33. The company has a quick ratio of 2.77, a current ratio of 2.77 and a debt-to-equity ratio of 0.05.

Gain Therapeutics (NASDAQ:GANX) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.08. As a group, equities research analysts predict that Gain Therapeutics will post -1.03 EPS for the current fiscal year.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.